The link you have selected will take you to a site outside xeneticbio.com.

Xenetic Biosciences, Inc. does not review or control the content of any non-Xenetic Biosciences, Inc. site. Xenetic Biosciences, Inc. does not endorse and is not responsible for the accuracy, content, practices, or standards of any non-Xenetic Biosciences, Inc. sites.

Xenetic Biosciences, Inc.

menu
  • Home
  • About
    • Overview
    • Management Team
    • Board of Directors
    • Scientific Advisory Board
    • Partners
    • Careers
  • Technology
    • DNase I Oncology Platform
    • Publications
  • Pipeline
    • Overview
    • XBIO-015
    • XBIO-020
  • News & Media
    • Press Releases
    • Presentations
  • Investors
    • Overview
    • News / Events
    • Company Information
    • Financial Information
    • Stock Data
    • Proxy Materials
    • SEC Filings
    • Corporate Governance
  • Contact
  • Xenetic Biosciences, Inc. on Twitter
  • Xenetic Biosciences, Inc. on Facebook
  • Xenetic Biosciences, Inc. on LinkedIn
Nasdaq: XBIO
News & Media

News & Media

  • Press Releases
  • Presentations

Press Releases

  • All News
  • 2025
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2017
  • 2016
  • 2015
  • 2014

Xenetic Biosciences Announces Collaboration with Excivion Ltd., UK, to Develop a Novel Combined Zika and Dengue Vaccine

Aug 18, 2016

Xenetic Biosciences Appoints Jeffrey F. Eisenberg to the Board of Directors

Jul 11, 2016

Xenetic Biosciences Announces Reverse Stock Split in Preparation for Proposed Uplisting to Nasdaq Capital Market

Jun 1, 2016

Xenetic Biosciences Appoints Renowned Chemist and Nobel Laureate, Dr. Roger D. Kornberg, to Board of Directors

Feb 29, 2016

OPKO Health Acquires Interest in Xenetic

Feb 12, 2016
  • « Previous
  • 1
  • 2

Get Email Alerts

Stay informed about our latest news and updates

Sign up Today
© 2025Xenetic Biosciences, Inc.
  • Privacy Policy
  • Disclaimer
  • Sitemap